All Cycles Name	NC/NA, %	Grade 1, %	Grade 2, %	Grade 3, %	Grade 4, %	Grade 5, %	All grades, %
Skin and subcutaneous tissue disorders	11	79	11	0	0	0	89
Lung infection	89	5	5	0	0	0	11
Pneumonitis	89	0	5	5	0	0	11
Esophagitis	53	32	16	0	0	0	47
Laryngitis	95	0	0	5	0	0	5
Constipation	74	16	11	0	0	0	26
Blurred vision	89	11	0	0	0	0	11
Proteinuria	63	37	0	0	0	0	37
Blood and lymphatic system disorders ‐ Leukopenia	68	16	11	5	0	0	32
Blood and lymphatic system disorders ‐ Neutrophilic granulopenia	68	0	32	0	0	0	32
Blood and lymphatic system disorders ‐ Lymphopenia	53	0	11	32	5	0	47
Anemia	95	5	0	0	0	0	5
Alanine aminotransferase increased	89	11	0	0	0	0	11
Hyperglycemia	74	26	0	0	0	0	26
Fatigue	95	0	5	0	0	0	5
Cough	95	0	0	5	0	0	5
Respiratory, thoracic and mediastinal disorders	84	16	0	0	0	0	16
Hypothyroidism	84	16	0	0	0	0	16

Treatment‐related adverse events occurring in all cycles.

All patients experienced some form of treatment‐related AEs (Table 2), but most were grade 1–2, and no grade 5 events were reported. The most common type of toxicity was cutaneous capillary hemangioma (15 [79%] with grade 1 and 2 [10%] with grade 3), which was the immune‐related AE; all cases were managed with local therapy or observation. Nine patients (47%) experienced grade 3 adverse events: six with lymphopenia (which was not treated), one with radiation pneumonitis, one with radiation laryngitis (treated with dexamethasone), and one with leukopenia (treated with granulocyte‐macrophage colony‐stimulating factor). The patient with radiation laryngitis had cervical esophageal cancer. One patient (5%) experienced grade 4 lymphopenia, which was not treated. Three patients experienced grade 1 hypothyroidism. Other organ‐specific immune‐related AEs, such as thyroiditis, stomatitis, and colitis, were not found.

Abbreviation: NC/NA, no change from baseline/no adverse event.